TGF-β in kidney fibrosis: A target for gene therapy
暂无分享,去创建一个
[1] T. Yamamoto,et al. Transforming Growth Factor β in Diabetic Nephropathy , 1996 .
[2] S. Thorgeirsson,et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[3] Y. Kaneda,et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney , 1996, Nature Medicine.
[4] C. Nast,et al. Expression of transforming growth factor-β isoforms in human glomerular diseases , 1996 .
[5] H. Blau,et al. Muscle-mediated gene therapy. , 1995, The New England journal of medicine.
[6] Helen M. Blau,et al. Molecular Medicine: Gene Therapy - A Novel Form of Drug Delivery , 1995 .
[7] K. Sharma,et al. Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator , 1995, Diabetes.
[8] C. Nast,et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. , 1995, Journal of the American Society of Nephrology.
[9] H. Schnaper,et al. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. , 1995, Kidney international.
[10] J. Wolff,et al. Direct gene transfer into muscle. , 1994, Vaccine.
[11] W. Border,et al. Transforming Growth Factor β in Tissue Fibrosis , 1994 .
[12] E. Ruoslahti,et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. , 1994, The Biochemical journal.
[13] T. Yamamoto,et al. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. , 1994, Kidney international.
[14] Y. Kaneda,et al. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. , 1993, The Journal of clinical investigation.
[15] D. Heinegård,et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. , 1993, The Journal of clinical investigation.
[16] E. Ruoslahti,et al. Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[17] E Ruoslahti,et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Sporn,et al. Transforming growth factor-beta: recent progress and new challenges , 1992, The Journal of cell biology.
[19] W. Border,et al. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. , 1992, Kidney international.
[20] S. J. Elliott,et al. The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of alpha 2IV collagen mRNA expression by competitive polymerase chain reaction , 1992, The Journal of experimental medicine.
[21] E. Ruoslahti,et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.
[22] E. Ruoslahti,et al. Transforming growth factor-beta in disease: the dark side of tissue repair. , 1992, The Journal of clinical investigation.
[23] M. Sporn,et al. Differential expression of the TGF‐β isoforms in embryogenesis suggests specific roles in developing and adult tissues , 1992, Molecular reproduction and development.
[24] T. Nakamura,et al. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. , 1992, Kidney international.
[25] D. Foreman,et al. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β , 1992, The Lancet.
[26] H. Larjava,et al. Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. , 1991, The Journal of biological chemistry.
[27] Erkki Ruoslahti,et al. Proteoglycans as modulators of growth factor activities , 1991, Cell.
[28] E. Ruoslahti,et al. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.
[29] M. Sporn,et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.
[30] M. Sporn,et al. Peptide Growth Factors and Their Receptors I , 1990, Handbook of Experimental Pharmacology.
[31] G. Acsadi,et al. Direct gene transfer into mouse muscle in vivo. , 1990, Science.
[32] T. Yamamoto,et al. Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. , 1987, Kidney international.
[33] J. Rozing,et al. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. , 1986, Laboratory investigation; a journal of technical methods and pathology.
[34] W. Bennett,et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. , 1996, Kidney international.
[35] P. Working,et al. Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits. , 1993, International review of experimental pathology.
[36] W. Border,et al. In vivo interactions of TGF-β and extracellular matrix , 1992 .
[37] J. McPherson,et al. Differences in the biological activities of transforming growth factor-beta and platelet-derived growth factor in vivo. , 1991, Growth factors.
[38] E. Ruoslahti,et al. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. , 1990, Kidney international.